The global orthopedic oncology treatment market is expected to grow by 2.5% by 2030
Orthopedic oncology represents a very small percentage in the field of orthopedics due to the fact that the incidence of bone and soft tissue tumors is rare compared to the benign tumors of the musculoskeletal system, which include trauma, spine, hand and upper extremity. , total joints and even pediatric orthopedics.
Tumors or tumor-like conditions sometimes appear in the bones and soft tissues of the musculoskeletal system; this condition is called bone cancer. Medical specialty concerned with the diagnosis and treatment of benign and malignant tumors of bone and soft tissue.
These tumors include Ewing’s sarcoma, osteosarcoma, and other malignancies involving the musculoskeletal system. Orthopedic oncology represents only a small percentage of the field of orthopedics. Even when benign tumors of the musculoskeletal system are included, the incidence of these conditions is negligible compared to trauma, spine, hand and upper limb, total joints, and even pediatric orthopedics.
However, orthopedic oncology continues to be reinvigorated by exciting developments and research that have advanced the treatment of patients with various bone and soft tissue tumors. Additional advances have come in the field of imaging. Computed tomography (CT) is used to identify lung metastases, which can be treated with chemotherapy and/or resection with potential for cure in many cases.
Magnetic resonance imaging (MRI) better defines the local extent of disease and ignores metastases to allow accurate definitive surgery and early detection of local recurrence. Finally, positron emission tomography (PET) is proving to be valuable in detecting local recurrence and may be a valuable predictor of response to chemotherapy in bone and soft tissue malignancies.
Orthopedic oncology represents a very small percentage in the field of orthopedics due to the fact that the incidences of bone and soft tissue tumors are rare compared to the benign tumors of the musculoskeletal system that include trauma, spine, hand and upper extremity, total joints and even pediatric orthopedics. However, the field of orthopedic oncology continues to be invigorated by exciting research and developments that have improved the level of treatment and care for patients with various bone and soft tissue tumors.
Currently, most patients with primary bone sarcomas receive limb-salvage surgery without increasing the risk of survival in sarcoma centers. In addition, advances in imaging and surgical techniques have further improved the management of patients with bone and soft tissue malignancies. Orthopedic oncologists continue to collaborate with other subspecialists to integrate advances in surgical techniques. This is especially true for implant development and image-guided surgery.
The global orthopedic oncology treatment market by types of procedures has been segmented into soft tissue excisions/resections, limb salvage surgery, amputation, adjuvant chemotherapy, and reconstructive surgery. Reconstructive surgery is further sub-segmented into hip and joint replacement and bone grafts.
The dominant segment is reconstructive surgery
Reconstructive surgery has the largest share of the global orthopedic oncology treatment market. Bone grafting techniques are anticipated to grow at the highest rate during the forecast period due to advancements in the field of prosthesis and endoprosthesis.
Latin AmericaThe middle Eastand Africa emerged as the most potential market
In base 2020, Asia Pacific was noted as the biggest market for the orthopedic oncology market. The high prevalence of disease, along with the growing health ecosystem in the region, has helped the growth of the orthopedic oncology market in Asia Pacific.
Furthermore, the growth of medical tourism in the region over the past decade has further fueled the orthopedic oncology treatment market in Asia Pacific. Latin AmericaThe middle Eastand Africa emerged as the most potential market due to the high prevalence of osteosarcoma and the lowest available treatment options in the region. Therefore, this market would exhibit a strong growth rate during the forecast period with the development of healthcare infrastructure.
Historical and forecast period
This report represents an analysis of each segment from 2020 to 2030 with 2021 as the base year. Compound annual growth rate (CAGR) for each of the respective estimated segments for the forecast period 2022 to 2030.
The current report includes quantitative market estimates for each micro market for each geographic region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, five forces of gatekeepers model, key strategies winners, key investment markets, emerging markets technology trends and analysis, case studies, strategic findings and recommendations, and other key market insights.
Key questions answered in this report
What are the key micro and macro environmental factors impacting the growth of the Orthopedic Oncology Treatment market?
What are the key investment pockets across product segments and geographies currently and over the forecast period?
Estimated forecast and market projections until 2030.
Which segment represents the fastest CAGR over the forecast period?
Which market segment holds the largest market share and why?
Are low- and middle-income economies investing in the orthopedic oncology treatment market?
What is the largest regional market for the Orthopedic Oncology Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin Americaand middle East & Africa?
What are the key trends driving the Orthopedic Oncology Treatment market?
Who are the main competitors and what are their main strategies to increase their presence in the global Orthopedic Oncology Treatment market?
Main topics covered:
2. Executive Summary
3. Orthopedic oncology treatment market: business prospects and market dynamics
3.2. Global market value of orthopedic oncology treatment, 2020-2030, (US$ million)
3.3. market dynamics
3.3.1. market drivers
3.3.2. market restrictions
3.3.3. main challenges
3.3.4. Main opportunities
3.4. Impact Analysis of Drivers and Restrictions
3.5. seesaw analysis
3.6. Porter’s Five Forces Model
3.6.1. Supplier Power
3.6.2. buyer power
3.6.3. threat of substitutes
3.6.4. Threat of new entrants
3.6.5. competitive rivalry
3.7. PESTEL Analysis
3.7.1. political landscape
3.7.2. economic scenario
3.7.3. Technological Scenario
3.7.4. Legal Scenario
3.7.5. Social Scenario
4. Orthopedic Oncology Treatment Market: By Procedure Type, 2020-2030, US$ (Million)
4.1. Market overview
4.2. Growth and revenue analysis: 2021 versus 2030
4.3. Market segmentation
4.3.1. Soft Tissue Excisions/Resections
4.3.2. Limb Saving Surgery
4.3.4. Adjuvant Chemotherapy
4.3.5. reconstructive surgery
18.104.22.168. Hip and Joint Replacement
22.214.171.124. Bone Grafts
5. North American Orthopedic Oncology Treatment Market, 2020-2030, US$ (million)
6. UK and EU Orthopedic Oncology Market, 2020-2030, US$ (million)
7. Orthopedic Cancer Treatment Market in Asia Pacific, 2020-2030, US$ (million)
8. Orthopedic Oncology Treatment Market in Latin America, 2020-2030, US$ (million)
9. middle East and Africa Orthopedic Oncology Treatment Market, 2020-2030, USD (million)
10. Company profiles
10.1. Stryker Corporation
10.1.1. Company Overview
10.1.2. financial performance
10.1.3. product portfolio
10.1.4. strategic initiatives
10.2. Zimmer Biomet Holdings, Inc.
10.2.1. Company Overview
10.2.2. financial performance
10.2.3. product portfolio
10.2.4. strategic initiatives
10.3. Smith & Nephew Plc
10.3.1. Company Overview
10.3.2. financial performance
10.3.3. product portfolio
10.3.4. strategic initiatives
10.4. DePuy Synthes (Johnson & Johnson)
10.4.1. Company Overview
10.4.2. financial performance
10.4.3. product portfolio
10.4.4. strategic initiatives
10.5.1. Company Overview
10.5.2. financial performance
10.5.3. product portfolio
10.5.4. strategic initiatives
10.6. Medical Stress
10.6.1. Company Overview
10.6.2. financial performance
10.6.3. product portfolio
10.6.4. strategic initiatives
10.7. Roche Holding AG
10.7.1. Company Overview
10.7.2. financial performance
10.7.3. product portfolio
10.7.4. strategic initiatives
10.8. Amgen, Inc.
10.8.1. Company Overview
10.8.2. financial performance
10.8.3. product portfolio
10.8.4. strategic initiatives
10.9. Novartis AG
10.9.1. Company Overview
10.9.2. financial performance
10.9.3. product portfolio
10.9.4. strategic initiatives
10.10.1. Company Overview
10.10.2. financial performance
10.10.3. product portfolio
10.10.4. strategic initiatives
10.11.1. Company Overview
10.11.2. financial performance
10.11.3. product portfolio
10.11.4. strategic initiatives
10.12. Pfizer Inc.
10.12.1. Company Overview
10.12.2. financial performance
10.12.3. product portfolio
10.12.4. strategic initiatives
For more information on this report, visit https://www.researchandmarkets.com/r/jtq4tr-orthopedic?w=5
Research and Markets
Laura WoodSenior manager
For EST office hours, call +1-917-300-0470
For US/CAN toll free calls +1-800-526-8630
For business hours GMT call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside US): +353-1-481-1716
See original content: https://www.prnewswire.com/news-releases/worldwide-orthopedic-oncology-treatment-industry-to-2030—dominating-segment-is-reconstructive-surgery-301730970.html
SOURCE Research and Markets